Oscar Health news

Zacks Rank #1 (Strong Buy); record first-half profitability; raised 2026 outlook; Q2 revenue surged to $4.9 billion from $2.9 billion year-over-year

Stock broke above 50-day moving average, gained 21.5% in four weeks, holds Zacks Rank #1 (Strong Buy) rating, and has received positive earnings estimate revisions with no downward adjustments in two months, suggesting strong near-term upside potential.

The article presents a highly bullish case for Oscar Health, highlighting rapid member growth (50% YoY), significant market share gains in a $1.6 trillion industry, upcoming profit inflection in 2026, and attractive valuation at 2.5x projected earnings at scale. The company's technology-driven approach and expansion into employer-funded plans position it for substantial long-term growth and stock appreciation.

Despite significant stock decline and macro headwinds (reduced subsidies, elevated healthcare costs), Oscar Health is rapidly gaining market share, growing to 3.4 million members, and positioned to return to profitability with $250-450M operating income guidance. Trading at less than 10x forward earnings with room for margin expansion makes it attractive for long-term investors.

Despite missing Q4 2025 estimates on both revenue and net loss, the stock rose on unexpectedly optimistic full-year 2026 guidance ($18.7-19B revenue, $250-450M operating earnings) and strong membership growth (2M+ members, up from 1.7M year-over-year). The author notes this is a company to watch if it can meet its projections.

Despite Q4 2025 earnings miss and operational losses, the company demonstrated strong membership growth (1.68M to 2.04M), secured favorable financing ($475M credit facility), and provided bullish 2026 guidance with projected operating earnings of $250-450M and revenue of $18.7-19B. Management expressed confidence in returning to profitability with new product offerings and AI features. Stock price rose 5.60% on the announcement.

Included as one of the three undervalued healthcare stocks highlighted in the article for potential investment.

Selected as one of four overlooked stocks with doubling potential; analyst maintains a position in the company, suggesting confidence in future performance.

Zacks Rank #1 rating, exceptional 210.2% earnings estimate increase over 60 days, low PEG ratio of 0.34 (below industry average of 0.92), and highest Growth Score of A indicate strong growth momentum and value.

Zacks Rank #1 rating, exceptional 227.7% increase in consensus earnings estimates over 60 days, favorable PEG ratio of 0.67 vs industry 0.91, and Growth Score of A indicate exceptional growth potential.

Zacks Rank #1 rating with exceptional 227.7% consensus earnings estimate increase over 60 days; PEG ratio of 0.62 below industry 0.95; Growth Score of B indicates strong growth potential.

Record first half 2026 results with raised full-year guidance, dramatic earnings estimate revision from $0.63 to $1.54 (191% growth), Zacks Rank #1 Strong Buy, attractive PEG ratio of 0.6

Zacks Rank #1 rating, exceptional 227.7% consensus earnings estimate increase over 60 days, favorable PEG ratio of 0.64 vs industry 1.00, and Growth Score of A indicate significant positive momentum.

Rapid customer growth from 1 million to 3.2 million paying customers since Q1 2022, cloud-based technology advantage over legacy competitors, achieving profitability with $19 billion revenue guidance, and current market cap of $6.8 billion appears undervalued relative to growth trajectory.

Oscar Health's earnings are mentioned alongside other companies covered in the video, but no specific performance details or sentiment indicators are provided in the article.

Disruptive ACA marketplace player with exceptional growth (3.4M members vs <1M in 2021). Despite elevated medical loss ratio in 2025, company expects $250-450M operating income in 2026 as pricing normalizes and scale increases. Low valuation at $4.3B market cap relative to growth trajectory.

Healthcare sector beaten down by spending cuts and reregulation fears; identified as value play with contrarian opportunity

Stock added 1.25% on positive sector sentiment from the Medicare Advantage payment increase announcement

Company is gaining market share in health insurance, expected to return to profitability in 2026 with $250-450M operating income guidance, and trades at a low market cap of $3.3B relative to growth prospects. Healthcare spending is stable during economic downturns.